您的位置: 首页 > 2015年7月 第46卷 第4期 > 文字全文
2023年7月 第38卷 第7期11
目录

改良INP方案对肺腺癌脑转移患者的疗效分析

Efficacy of chemotherapy of modified INP regimen for adenocarcinoma with brain metastases

来源期刊: 广州医药 | 13-16 发布时间:2021-11-30 收稿时间:2025/11/13 16:44:07 阅读量:19
作者:
关键词:
肺腺癌异环磷酰胺长春瑞滨β微管蛋白Ⅲ型脑转移癌
AdenocarcinomaIfosfamideVinorelbineβ-tubulin-ⅢBrain metastases
DOI:
10.3969/j.issn.1000-8535.2015.04.004
收稿时间:
2015-02-27 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 观察改良INP方案对肺腺癌伴有脑转移患者的临床疗效及毒副作用,并探讨该方案疗效与Ⅲ型β微管蛋白(β-tubulin-Ⅲ)在肺癌组织中表达水平的关系。方法 收集2010年4月—2013年1月广州医科大学附属第一医院胸外科收治的15例肺腺癌伴有脑转移患者的临床资料。所有患者均采用改良INP方案治疗,使用RECIST 1.0标准进行判定。结果 脑转移瘤取得CR 1例(1/15),PR 5例(5/15),SD 4例(4/15),PD 5例 (5/10),该方案对脑转移瘤的总缓解率(overall response rate,ORR)为40%,疾病控制率(disease control rate,DCR)达66.7%,毒副作用轻度可控;Ⅲ型β微管蛋白低表达对该方案的疗效有优于高表达的趋势。结论 肺腺癌伴有脑转移患者采用改良INP方案进行化疗,脑转移瘤临床疾病控制率较高,耐受性良好;肿瘤组织β-tubulin-Ⅲ表达水平可能与该方案的疗效相关。
Objective To investigate the efficacy and toxicity of chemotherapy of modified INP regimen in the treatment of adenocarcinoma with brain metastases. At the same time,to explore the relationship between expression of β-tubulin-Ⅲ in NSCLC biopsies and sensitivity to this modified INP regimen. Methods The clinical data of 15 adenocarcinoma with brain metastases patients who had been admitted to the first affiliated hospital of Guangzhou medical university from April 2010 to January 2013 were retrospectively analyzed. All patients received modified INP regimen.RECIST 1.0 was taken to know the result. Results For brain metastasis of the 15 patients, complete response (CR) and partial response(PR) were 1 and 5 patients, respectively. 4 patients were stable disease (SD) and progression disease(PD) in 5 patients. The overall response rate(ORR) was 40% and the disease control rate(DCR) was 66.7%. The toxicity was mild. Furthermore, we found NSCLC patients with low β-tubulin-Ⅲexpression had better ORR than those with high expression. Conclusion The modified INP regimen is effective and well-tolerable for brain metastases of adenocarcinoma. The β-tubulin-Ⅲ expression may be associated with the efficacy of this regimen.
1、 张亚雷,杨海虹,邓秋华,等.改良INP方案对晚期非小细胞肺癌患者疗效分析[J]. 实用肿瘤杂志,2013,3(28):312-315. 张亚雷,杨海虹,邓秋华,等.改良INP方案对晚期非小细胞肺癌患者疗效分析[J]. 实用肿瘤杂志,2013,3(28):312-315.
2、 梁颖,徐光川,陈丽昆,等.INP和NP方案治疗晚期非小细胞肺癌的随机研究[J]. 中山大学学报(医学科学版), 2004,25(3S):225-228. 梁颖,徐光川,陈丽昆,等.INP和NP方案治疗晚期非小细胞肺癌的随机研究[J]. 中山大学学报(医学科学版), 2004,25(3S):225-228.
3、 Rosell R,Scagliotti G,Danenberg KD,et al. Transcfipts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer[J]. Onengene,2003,22(23):3548-3553. Rosell R,Scagliotti G,Danenberg KD,et al. Transcfipts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer[J]. Onengene,2003,22(23):3548-3553.
4、 Yang YL, Luo XP, Xian L.The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis[J]. PLoS One, 2014,9(4):e93997. Yang YL, Luo XP, Xian L.The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis[J]. PLoS One, 2014,9(4):e93997.
5、 Snson M,Ameri A,Monjour A,et al. Treatment of recurrent malignant supratentorial gliomas with ifosfamide,carboplatin and etoposide:a phase Ⅱ study[J]. Eur J Cancer,1996,(32A):2229-2235. Snson M,Ameri A,Monjour A,et al. Treatment of recurrent malignant supratentorial gliomas with ifosfamide,carboplatin and etoposide:a phase Ⅱ study[J]. Eur J Cancer,1996,(32A):2229-2235.
6、 Lucie L,Donald JM,Willian H,et al. Use of ifosfamide,carboplatin,and etoposide chemotherapy in choroids plexus carcinoma[J]. Journal of Neurosurgery:Pediatrics,2010,5(6):615-621 Lucie L,Donald JM,Willian H,et al. Use of ifosfamide,carboplatin,and etoposide chemotherapy in choroids plexus carcinoma[J]. Journal of Neurosurgery:Pediatrics,2010,5(6):615-621
7、 宋俊彪,路萍.国产长春.瑞滨联合顺铂治疗晚期非小细胞肺癌的临床观察[J]. 哈尔滨医药,2006,26(6):2-4. 宋俊彪,路萍.国产长春.瑞滨联合顺铂治疗晚期非小细胞肺癌的临床观察[J]. 哈尔滨医药,2006,26(6):2-4.
8、 Quantin X, Khial F, Reme Saumon M. Concomitant brain radiotherapy and vinorelbine-ifosfamind-cisplatin chemotherapy in brain metastases of non-small cell lung cancer[J]. Lung cancer,1999,26(1):35-39 Quantin X, Khial F, Reme Saumon M. Concomitant brain radiotherapy and vinorelbine-ifosfamind-cisplatin chemotherapy in brain metastases of non-small cell lung cancer[J]. Lung cancer,1999,26(1):35-39
9、 Furuse K,Kamimori T,Kawahara M. A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin,vindesine and mitomycin in non-small cell lung cancer with brain metastasis[J]. Br J Cancer, 1997,75(4):614-618. Furuse K,Kamimori T,Kawahara M. A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin,vindesine and mitomycin in non-small cell lung cancer with brain metastasis[J]. Br J Cancer, 1997,75(4):614-618.
10、 Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain?[J]. Cancer Chemother Pharmacol, 1992,30(4):251-260 Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain?[J]. Cancer Chemother Pharmacol, 1992,30(4):251-260
11、 吴煌坚,蔡悦成,李曙平,等.23例脑转移的放射治疗[J]. 广州医药,2002,33(6):11-12 吴煌坚,蔡悦成,李曙平,等.23例脑转移的放射治疗[J]. 广州医药,2002,33(6):11-12
12、 Baykara M, Kurt G, Buyukberber S, et al. Management of brain metastases from non-small cell lung cancer[J]. J Cancer Res Ther,2014,10(4):915-21. Baykara M, Kurt G, Buyukberber S, et al. Management of brain metastases from non-small cell lung cancer[J]. J Cancer Res Ther,2014,10(4):915-21.
13、 Pirker R. Two-versus three-drug combinations in the chemotherapy of advanced non-small cell lung cancer[J]. Lung Cancer, 2002,38 (Suppl 3):S53-S55. Pirker R. Two-versus three-drug combinations in the chemotherapy of advanced non-small cell lung cancer[J]. Lung Cancer, 2002,38 (Suppl 3):S53-S55.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录